| 000 | 01771 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517141439.0 | ||
| 264 | 0 | _c20170306 | |
| 008 | 201703s 0 0 eng d | ||
| 022 | _a1539-6304 | ||
| 024 | 7 |
_a10.2500/aap.2017.38.4034 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiller, David | |
| 245 | 0 | 0 |
_aA randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma. _h[electronic resource] |
| 260 |
_bAllergy and asthma proceedings _cMar 2017 |
||
| 300 |
_a157-164 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Asthmatic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAsthma _xdrug therapy |
| 650 | 0 | 4 |
_aBenzamides _xtherapeutic use |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluticasone _xtherapeutic use |
| 650 | 0 | 4 | _aForced Expiratory Volume |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPyrimidines _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptors, Immunologic _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aReceptors, Prostaglandin _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aVital Capacity |
| 700 | 1 | _aWood, Chester | |
| 700 | 1 | _aBateman, Eric | |
| 700 | 1 | _aLaForce, Craig | |
| 700 | 1 | _aBlatchford, Jon | |
| 700 | 1 | _aHilbert, James | |
| 700 | 1 | _aGupta, Abhya | |
| 700 | 1 | _aFowler, Andrew | |
| 773 | 0 |
_tAllergy and asthma proceedings _gvol. 38 _gno. 2 _gp. 157-164 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2500/aap.2017.38.4034 _zAvailable from publisher's website |
| 999 |
_c26910618 _d26910618 |
||